Flexion Therapeutics Q3 EPS $(1) Misses $(0.96) Estimate, Sales $21.786M Beat $19.01M Estimate

Flexion Therapeutics (NASDAQ:FLXN) reported quarterly losses of $(1) per share which missed the analyst consensus estimate of $(0.96) by 4.17 percent. This is a 13.04 percent increase over losses of $(1.15) per share

Benzinga · 11/07/2019 21:02

Flexion Therapeutics (NASDAQ:FLXN) reported quarterly losses of $(1) per share which missed the analyst consensus estimate of $(0.96) by 4.17 percent. This is a 13.04 percent increase over losses of $(1.15) per share from the same period last year. The company reported quarterly sales of $21.786 million which beat the analyst consensus estimate of $19.01 million by 14.60 percent. This is a 211.67 percent increase over sales of $6.99 million the same period last year.